Opioid Overdose Deaths in New Jersey: Data and Trends

Key Takeaways

• New Jersey consistently ranks among the states with the highest per-capita rates of drug overdose deaths in the United States.
• Fentanyl-involved deaths have become the dominant driver of NJ’s overdose crisis, surpassing heroin, prescription opioids, and all other drug categories.
• Polysubstance combinations — particularly fentanyl with xylazine, cocaine, or benzodiazepines — represent an increasing share of overdose fatalities.
• Overdose death rates vary significantly by county, with both urban and suburban areas affected.
• New Jersey’s response includes expanded naloxone (Narcan) access, the Good Samaritan Law, the NJ CARES initiative, and harm reduction programs.
• Data is sourced primarily from the NJ Office of the Chief State Medical Examiner (OCSME) and the NJ CARES dashboard.

The opioid overdose crisis in New Jersey is not a historical event — it is an ongoing public health emergency that has evolved through several phases, each with distinct characteristics. Understanding the data — where deaths are occurring, which substances are involved, and how the landscape is changing — is essential for individuals, families, policymakers, and treatment providers making decisions in real time.

This page presents the available data on opioid overdose deaths in New Jersey, with analysis of trends, geographic patterns, and the state’s policy responses.

New Jersey’s Opioid Overdose Crisis by the Numbers

Statewide Death Totals and Trends

New Jersey’s overdose death trajectory reflects the national pattern but with state-specific characteristics. The crisis has evolved through three overlapping waves:

Wave 1 (early 2000s-2010): Driven primarily by prescription opioid misuse. Aggressive marketing of opioid painkillers and liberal prescribing practices led to widespread dependence. Deaths during this period primarily involved prescription opioids like oxycodone and hydrocodone.

Wave 2 (2010-2015): As prescribing restrictions tightened and prescription opioids became harder to obtain, many individuals transitioned to heroin. Heroin-involved deaths rose sharply during this period.

Wave 3 (2015-present): Illicitly manufactured fentanyl (IMF) flooded the drug supply, producing a dramatic escalation in overdose deaths. Fentanyl is now present in the majority of overdose deaths in New Jersey.

According to the NJ Office of the Chief State Medical Examiner (OCSME), the state has experienced thousands of confirmed drug-related deaths annually in recent years. The NJ CARES dashboard provides regularly updated data on these trends.

How NJ Compares Nationally

New Jersey’s overdose death rate has consistently exceeded the national average. According to CDC data:

• NJ ranks among the top states nationally in age-adjusted overdose death rates
• The state’s per-capita rate of opioid-involved deaths places it well above the national median
• NJ’s proximity to major East Coast drug distribution corridors contributes to high availability of illicit fentanyl
• The state’s dense population, extensive transportation networks, and large number of individuals with substance use disorders create concentrated risk

New Jersey’s rates are broadly comparable to other hard-hit northeastern states including West Virginia, Pennsylvania, Ohio, and Connecticut, though the specific substances and demographic patterns vary.

The Fentanyl Factor in NJ Overdose Deaths

Fentanyl-Involved Deaths Over Time

The rise of fentanyl in New Jersey’s overdose data has been swift and transformative:

• In the early 2010s, fentanyl was present in a small fraction of overdose deaths
• By the mid-2010s, fentanyl-involved deaths were climbing rapidly
• In recent years, fentanyl has been identified in the majority of drug overdose deaths in New Jersey — frequently as the primary cause of death
• The NJ OCSME reports that fentanyl has surpassed all other substances as the leading cause of overdose mortality in the state

This shift reflects a fundamental change in the drug supply rather than a change in user behavior. Many individuals who die from fentanyl exposure did not knowingly use fentanyl — they purchased heroin, counterfeit pills, or other substances that were contaminated with or entirely replaced by fentanyl.

Polysubstance Use Patterns

Overdose deaths in New Jersey increasingly involve multiple substances. Patterns documented by the OCSME include:

Fentanyl + cocaine: A growing combination reflecting fentanyl contamination of the stimulant supply. Individuals who use cocaine may not realize their drug contains fentanyl, and cocaine users who lack opioid tolerance are particularly vulnerable.

Fentanyl + xylazine: Xylazine (an animal tranquilizer not approved for human use) has become an increasingly common adulterant in the fentanyl supply. Xylazine produces additional sedation, extends the fentanyl high, but also causes severe skin ulcerations and tissue necrosis at injection sites. Critically, xylazine does not respond to naloxone (Narcan), complicating overdose reversal.

Fentanyl + benzodiazepines: Both prescription and illicit benzodiazepines (including novel “designer” benzodiazepines) are frequently detected alongside fentanyl in overdose deaths. The combination of a CNS depressant with a potent opioid dramatically increases respiratory depression risk.

Fentanyl + alcohol: Alcohol potentiates the respiratory depressant effects of opioids and is detected in a notable proportion of overdose deaths.

These polysubstance patterns complicate both overdose prevention and treatment planning.

County-Level Overdose Data in New Jersey

Hardest-Hit Counties

Overdose deaths are not evenly distributed across New Jersey. While every county has been affected, some have consistently reported higher rates:

The NJ CARES dashboard provides county-level data that shows variation across the state. Generally:

• Urban counties with larger populations report higher absolute numbers of overdose deaths
• Per-capita rates reveal a more nuanced picture, with some suburban and rural counties showing rates comparable to or exceeding urban areas
• Camden, Essex, Atlantic, and Passaic counties have historically been among the hardest hit in absolute numbers
• Ocean, Burlington, and Monmouth counties have experienced significant suburban overdose crises

County-level data is important for resource allocation, treatment planning, and understanding local risk factors.

Urban vs. Suburban vs. Rural Patterns

The opioid crisis in New Jersey has defied the common assumption that drug addiction is primarily an urban problem:

• Urban areas: High population density, established drug markets, and concentrated poverty contribute to high overdose numbers. However, urban areas also tend to have more treatment resources.
• Suburban communities: The “pipeline” from prescription opioid misuse to heroin and fentanyl has hit suburban areas particularly hard. Communities in Ocean County, Monmouth County, and other traditionally suburban areas have experienced overdose rates rivaling urban centers.
• Rural areas: While NJ is predominantly urban/suburban, its more rural areas face challenges including limited treatment access, fewer naloxone distribution points, and longer EMS response times.

This geographic spread underscores that opioid use disorder does not discriminate by community type.

New Jersey’s Response to the Overdose Crisis

Naloxone Distribution Programs

New Jersey has been among the most aggressive states in expanding naloxone (Narcan) access:

• Statewide standing order: All New Jersey pharmacies can dispense naloxone without an individual prescription. Patients can request naloxone directly from a pharmacist.
• Community distribution: The NJ Department of Health funds organizations to distribute free naloxone kits in communities with high overdose rates.
• First responder access: All NJ law enforcement officers are trained and equipped to administer naloxone. EMS responders carry both intranasal and injectable formulations.
• Harm reduction organizations: NJ’s syringe access programs and harm reduction centers provide naloxone training and free kits.
• Narcan vending machines: Some NJ locations have installed naloxone vending machines for 24/7 access.

The NJ Prescription Drug Monitoring Program (NJ PDMP) also plays a role in prevention by allowing prescribers and pharmacists to review a patient’s controlled substance history before dispensing opioids.

Harm Reduction Initiatives

Beyond naloxone, New Jersey has implemented multiple harm reduction strategies:

• Good Samaritan Law (Overdose Prevention Act): Provides legal protections for individuals who call 911 during an overdose. Both the caller and the person experiencing the overdose are protected from drug possession charges.
• Syringe access programs: NJ has expanded access to sterile injection equipment to reduce HIV and hepatitis C transmission among people who inject drugs.
• Fentanyl test strips: Legal in New Jersey and distributed by harm reduction organizations, these allow individuals to test substances for fentanyl before use.
• NJ CARES initiative: Coordinates rapid access to treatment, including warm handoffs from emergency departments to treatment providers within 24 hours.
• Recovery support infrastructure: State-funded Peer Recovery Specialists deployed in hospitals, treatment centers, and community settings.
• Medication-assisted treatment expansion: NJ has expanded Medicaid coverage for MAT and promoted the use of buprenorphine (Suboxone/Sublocade) and methadone (Dolophine/Methadose) in a variety of settings.

Where the Data Comes From

NJ CARES Dashboard

The NJ CARES (Coordinated Addiction Response Efforts by the State) dashboard is the primary public resource for overdose data in New Jersey. It aggregates information from multiple sources:

• Medical examiner data: The NJ Office of the Chief State Medical Examiner (OCSME) conducts toxicology testing on all suspected drug-related deaths, providing the most definitive substance identification data.
• Emergency department visits: EMS and emergency department data capture non-fatal overdoses and related presentations.
• Naloxone administration data: Tracks where and how often naloxone is deployed by first responders and community members.
• Treatment admission data: Monitors treatment access and utilization patterns across the state.

The dashboard is updated regularly and allows filtering by county, substance, and time period.

NJDOH Reporting and Limitations

While New Jersey’s overdose data infrastructure is more robust than many states, important limitations exist:

• Reporting lag: Medical examiner data typically involves a lag of several months between a death and final toxicology results, meaning the most recent data may undercount.
• Cause of death classification: Not all drug-involved deaths are classified identically, and the presence of multiple substances can complicate attribution.
• Non-fatal overdose undercounting: Many non-fatal overdoses are reversed by bystanders with naloxone and never result in medical contact, making them invisible to surveillance systems.
• Xylazine and novel substances: Toxicology panels may not test for all emerging adulterants, potentially undercounting the presence of substances like xylazine, nitazenes, and novel synthetic opioids.
• Demographic data limitations: Race, ethnicity, and socioeconomic data in overdose reporting may be incomplete, limiting the ability to identify and address disparities.

Understanding these limitations is important for interpreting the data accurately. The numbers presented in any source represent confirmed cases and likely underestimate the true scope of the crisis.

---

This article is part of our complete guide to opioid addiction in New Jersey. For information about fentanyl specifically, see fentanyl addiction: signs, dangers, and treatment. For more on the prescribing landscape, visit prescription painkiller addiction.

For additional statistics, see our NJ overdose statistics page and national overdose statistics.